Together with the Quebec Consortium for Drug Discovery (CQDM), Brain Canada is pleased to share an upcoming funding opportunity for Canadian researchers. CQDM’s Quantum Leap pharma-led funding program for drug discovery research aims to support innovative translational biopharmaceutical research projects that are at advanced stages of development and that have the potential to improve, facilitate and/or accelerate the drug discovery process and the development of safer and more effective drugs.
Projects selected as part of the Quantum Leap program focus on developing cutting-edge technologies with the potential to significantly advance the R&D activities of CQDM’s pharmaceutical members. Quantum Leap projects are executed in close collaboration and with the expert support and funds of pharmaceutical members.
Brain Canada is partnering with the Quantum Leap pharma-led funding program for drug discovery research on eligible brain related projects.
Please note: Budget structures can vary depending on each project, please contact CQDM to confirm eligibility before applying.
For more details, please email CQDM at email@example.com and visit their website here.
Funding for the Quantum Leap partnership has been made possible thanks to Brain Canada and the CQDM.
Call for proposals are open year-round for Quantum Leap projects.
Deadline to participate in the next selection round : February 24, 2022.